Kangfang Biotech: Ivosidenib combined chemotherapy for first-line sq-NSCLC approved for market launch.

On August 12, Kangfang Biotech announced that the drug application for its globally innovative cornerstone drug, Yidafang, combined with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer, has been approved for market launch by the National Medical Products Administration.